Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
NeoGenomics management to meet virtually with BTIG » 04:55
05/10/21
05/10
04:55
05/10/21
04:55
NEO

NeoGenomics

$41.14 /

-0.87 (-2.07%)

Virtual Meeting to be…

Virtual Meeting to be held on May 10 hosted by BTIG.

ShowHide Related Items >><<
NEO NeoGenomics
$41.14 /

-0.87 (-2.07%)

NEO NeoGenomics
$41.14 /

-0.87 (-2.07%)

02/25/21 Craig-Hallum
NeoGenomics price target raised to $65 from $50 at Craig-Hallum
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform on valuation at Raymond James
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform from Outperform at Raymond James
01/27/21 Truist
NeoGenomics initiated with a Buy at Truist
NEO NeoGenomics
$41.14 /

-0.87 (-2.07%)

  • 07
    Jan
NEO NeoGenomics
$41.14 /

-0.87 (-2.07%)

Over a week ago
Hot Stocks
NeoGenomics to acquire remainder of Inivata for $390M » 07:25
05/05/21
05/05
07:25
05/05/21
07:25
NEO

NeoGenomics

$47.46 /

-0.05 (-0.11%)

Inivata announces that…

Inivata announces that NeoGenomics,has agreed to acquire Inivata. The acquisition follows a $25M minority equity investment by NeoGenomics in Inivata in May 2020, at which time NeoGenomics was granted a fixed price option to purchase the remainder of Inivata for $390M.

ShowHide Related Items >><<
NEO NeoGenomics
$47.46 /

-0.05 (-0.11%)

NEO NeoGenomics
$47.46 /

-0.05 (-0.11%)

02/25/21 Craig-Hallum
NeoGenomics price target raised to $65 from $50 at Craig-Hallum
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform on valuation at Raymond James
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform from Outperform at Raymond James
01/27/21 Truist
NeoGenomics initiated with a Buy at Truist
NEO NeoGenomics
$47.46 /

-0.05 (-0.11%)

  • 07
    Jan
NEO NeoGenomics
$47.46 /

-0.05 (-0.11%)

Conference/Events
NeoGenomics management to meet virtually with BTIG » 12:21
05/03/21
05/03
12:21
05/03/21
12:21
NEO

NeoGenomics

$48.25 /

-0.74 (-1.51%)

Virtual Meeting to be…

Virtual Meeting to be held on May 10 hosted by BTIG.

ShowHide Related Items >><<
NEO NeoGenomics
$48.25 /

-0.74 (-1.51%)

NEO NeoGenomics
$48.25 /

-0.74 (-1.51%)

02/25/21 Craig-Hallum
NeoGenomics price target raised to $65 from $50 at Craig-Hallum
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform on valuation at Raymond James
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform from Outperform at Raymond James
01/27/21 Truist
NeoGenomics initiated with a Buy at Truist
NEO NeoGenomics
$48.25 /

-0.74 (-1.51%)

  • 07
    Jan
NEO NeoGenomics
$48.25 /

-0.74 (-1.51%)

Over a month ago
Hot Stocks
NeoGenomics to acquire Trapelo Health for $35M in cash, $30M in stock » 07:19
03/24/21
03/24
07:19
03/24/21
07:19
NEO

NeoGenomics

$48.73 /

-2.22 (-4.36%)

NeoGenomics announced…

NeoGenomics announced that it has agreed to acquire Intervention Insights, doing business as Trapelo Health, an information technology company focused on precision oncology. The agreement purchase price of $65M, consisting of $35M in cash on hand and $30M in NeoGenomics common stock is subject to satisfaction of certain customary closing conditions and is expected to close in April. Trapelo Health's products advance the appropriate use of precision oncology. The company offers a interoperable, decision-support platform for physicians, laboratories, and payers to inform testing and treatment selection, improve clinical trials matching, streamline workflow and facilitate real-time alignment with the most current clinical evidence. The company said Trapelo is powered by a precision oncology knowledge system built on a proprietary technology and data-driven, evidence-based framework which consistently captures and codifies results of clinical research immediately as it becomes available.

ShowHide Related Items >><<
NEO NeoGenomics
$48.73 /

-2.22 (-4.36%)

NEO NeoGenomics
$48.73 /

-2.22 (-4.36%)

02/25/21 Craig-Hallum
NeoGenomics price target raised to $65 from $50 at Craig-Hallum
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform on valuation at Raymond James
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform from Outperform at Raymond James
01/27/21 Truist
NeoGenomics initiated with a Buy at Truist
NEO NeoGenomics
$48.73 /

-2.22 (-4.36%)

  • 07
    Jan
  • 30
    Apr
NEO NeoGenomics
$48.73 /

-2.22 (-4.36%)

Hot Stocks
NeoGenomics, Elevation Oncology announce collaboration » 07:06
03/16/21
03/16
07:06
03/16/21
07:06
NEO

NeoGenomics

$49.96 /

+0.72 (+1.46%)

Elevation Oncology and…

Elevation Oncology and NeoGenomics announced a collaboration to enhance identification of patients with any solid tumor harboring an NRG1 fusion who may be eligible for enrollment in the Phase 2 CRESTONE study. NeoGenomics is a leading provider of next-generation sequencing performing more than 50,000 NGS tests per year.

ShowHide Related Items >><<
NEO NeoGenomics
$49.96 /

+0.72 (+1.46%)

NEO NeoGenomics
$49.96 /

+0.72 (+1.46%)

02/25/21 Craig-Hallum
NeoGenomics price target raised to $65 from $50 at Craig-Hallum
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform on valuation at Raymond James
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform from Outperform at Raymond James
01/27/21 Truist
NeoGenomics initiated with a Buy at Truist
NEO NeoGenomics
$49.96 /

+0.72 (+1.46%)

  • 07
    Jan
  • 30
    Apr
NEO NeoGenomics
$49.96 /

+0.72 (+1.46%)

Conference/Events
NeoGenomics management to meet virtually with BTIG » 04:55
03/15/21
03/15
04:55
03/15/21
04:55
NEO

NeoGenomics

$49.28 /

+1.09 (+2.26%)

Virtual Meeting to be…

Virtual Meeting to be held on March 15 hosted by BTIG.

ShowHide Related Items >><<
NEO NeoGenomics
$49.28 /

+1.09 (+2.26%)

NEO NeoGenomics
$49.28 /

+1.09 (+2.26%)

02/25/21 Craig-Hallum
NeoGenomics price target raised to $65 from $50 at Craig-Hallum
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform on valuation at Raymond James
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform from Outperform at Raymond James
01/27/21 Truist
NeoGenomics initiated with a Buy at Truist
NEO NeoGenomics
$49.28 /

+1.09 (+2.26%)

  • 07
    Jan
  • 30
    Apr
NEO NeoGenomics
$49.28 /

+1.09 (+2.26%)

Conference/Events
NeoGenomics management to meet virtually with BTIG » 12:58
03/10/21
03/10
12:58
03/10/21
12:58
NEO

NeoGenomics

$46.38 /

+1.46 (+3.25%)

Virtual Meeting to be…

Virtual Meeting to be held on March 15 hosted by BTIG.

ShowHide Related Items >><<
NEO NeoGenomics
$46.38 /

+1.46 (+3.25%)

NEO NeoGenomics
$46.38 /

+1.46 (+3.25%)

02/25/21 Craig-Hallum
NeoGenomics price target raised to $65 from $50 at Craig-Hallum
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform on valuation at Raymond James
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform from Outperform at Raymond James
01/27/21 Truist
NeoGenomics initiated with a Buy at Truist
NEO NeoGenomics
$46.38 /

+1.46 (+3.25%)

  • 07
    Jan
  • 30
    Apr
NEO NeoGenomics
$46.38 /

+1.46 (+3.25%)

Recommendations
NeoGenomics price target raised to $65 from $50 at Craig-Hallum » 09:36
02/25/21
02/25
09:36
02/25/21
09:36
NEO

NeoGenomics

$54.33 /

+1.32 (+2.49%)

Craig-Hallum analyst…

Craig-Hallum analyst Alexander Nowak raised the firm's price target on NeoGenomics to $65 from $50 and keeps a Buy rating on the shares. The analyst argues that an in-line quarter reveals the potential of NeoGenomics as a high-growth cancer services business.

ShowHide Related Items >><<
NEO NeoGenomics
$54.33 /

+1.32 (+2.49%)

NEO NeoGenomics
$54.33 /

+1.32 (+2.49%)

02/25/21 Raymond James
NeoGenomics downgraded to Market Perform on valuation at Raymond James
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform from Outperform at Raymond James
01/27/21 Truist
NeoGenomics initiated with a Buy at Truist
12/11/20 BTIG
NeoGenomics initiated with a Buy at BTIG
NEO NeoGenomics
$54.33 /

+1.32 (+2.49%)

  • 07
    Jan
  • 30
    Apr
NEO NeoGenomics
$54.33 /

+1.32 (+2.49%)

Downgrade
NeoGenomics downgraded to Market Perform on valuation at Raymond James » 07:52
02/25/21
02/25
07:52
02/25/21
07:52
NEO

NeoGenomics

$54.33 /

+1.32 (+2.49%)

Raymond James analyst…

Raymond James analyst Andrew Cooper downgraded NeoGenomics to Market Perform from Outperform without a price target. The company's fundamental outlook and M&A potential are fairly well understood in the market, Cooper tells investors in a research note. As such, the analyst believes the current valuation offers limited near-term upside.

ShowHide Related Items >><<
NEO NeoGenomics
$54.33 /

+1.32 (+2.49%)

NEO NeoGenomics
$54.33 /

+1.32 (+2.49%)

02/25/21 Raymond James
NeoGenomics downgraded to Market Perform from Outperform at Raymond James
01/27/21 Truist
NeoGenomics initiated with a Buy at Truist
12/11/20 BTIG
NeoGenomics initiated with a Buy at BTIG
11/20/20 SVB Leerink
NeoGenomics price target raised to $50 from $47 at SVB Leerink
NEO NeoGenomics
$54.33 /

+1.32 (+2.49%)

  • 07
    Jan
  • 30
    Apr
NEO NeoGenomics
$54.33 /

+1.32 (+2.49%)

Downgrade
NeoGenomics downgraded to Market Perform from Outperform at Raymond James » 04:47
02/25/21
02/25
04:47
02/25/21
04:47
NEO

NeoGenomics

$54.33 /

+1.32 (+2.49%)

Raymond James analyst…

Raymond James analyst Andrew Cooper downgraded NeoGenomics to Market Perform from Outperform without a price target.

ShowHide Related Items >><<
NEO NeoGenomics
$54.33 /

+1.32 (+2.49%)

NEO NeoGenomics
$54.33 /

+1.32 (+2.49%)

01/27/21 Truist
NeoGenomics initiated with a Buy at Truist
12/11/20 BTIG
NeoGenomics initiated with a Buy at BTIG
11/20/20 SVB Leerink
NeoGenomics price target raised to $50 from $47 at SVB Leerink
10/28/20 Needham
NeoGenomics price target raised to $46 from $39 at Needham
NEO NeoGenomics
$54.33 /

+1.32 (+2.49%)

  • 07
    Jan
  • 30
    Apr
NEO NeoGenomics
$54.33 /

+1.32 (+2.49%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.